Critical Milestones Loom for Arrowhead Pharmaceuticals
Published on 10/15/2025 at 06:54 | Redaktion boerse-global.de
Arrowhead Pharmaceuticals stands at a pivotal juncture, with two significant regulatory developments poised to shape its commercial future. The biotechnology firm is advancing preparations for its first commercial drug launch while simultaneously progressing another innovative therapy through clinical pipelines.
The company faces a decisive FDA PDUFA date for Plozasiran on November 18, representing Arrowhead’s potential breakthrough into commercial markets. This therapeutic candidate targets familial chylomicronemia syndrome (FCS), a rare metabolic disorder.
Concurrently, Arrowhead has achieved another clinical milestone with the October 7 submission of ARO-DIMER-PA for regulatory approval. This novel RNA interference therapy addresses mixed hyperlipidemia and marks the first dual-functional RNAi treatment of its kind in development.
Financial Foundation Supports Operations
Substantial financial resources underpin Arrowhead’s... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
